Trial Profile
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GEMINI 2; GEMINI-II
- Sponsors Millennium
- 17 Oct 2023 Results comparing discontinuation rates due to lack of efficacy during maintenance treatment with infliximab or vedolizumab in patients with Crohn'S Disease (NCT02883452, NOR-SWITCH, PLANETCD, and LIBERTY-CD) infliximab and two RCTs (GEMINI 2 and VISIBLE 2) on vedolizumab, presented at the 31st United European Gastroenterology Week.
- 23 May 2021 Results of post-hoc analysis presented at the Digestive Disease Week 2021.
- 22 Dec 2019 Results, an analysis of the data from GEMINI-2 study,GETAID and VICTORY dataset assessing the role of clinical decision support tool (CDST) in predicting efficacy of vedolizumab in Crohn's disease, published in the Alimentary Pharmacology and Therapeutics